1.
A periodicity of ∼1 hour in X-ray emission from the active galaxy RE J1034+396
by Gierli ski, Marek
Nature (London), 2008, Vol.455 (7211), p.369-371
2.
A periodicity of approximately 1 hour in X-ray emission from the active galaxy RE J1034+396
by Gierliński, Marek
Nature (London), 2008, Vol.455 (7211), p.369-371
3.
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
by Seymour, Matthew T, Prof
The Lancet (British edition), 2011, Vol.377 (9779), p.1749-1759
4.
Potential research participants support the return of raw sequence data
by Middleton, Anna
Journal of medical genetics, 2015, Vol.52 (8), p.571-574
5.
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomi...
by Seymour, Matthew T, Prof
The lancet oncology, 2013, Vol.14 (8), p.749-759
6.
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
by Maughan, Timothy S, Prof
The Lancet (British edition), 2011, Vol.377 (9783), p.2103-2114
7.
Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy
by van Leeuwen, Marina T
AIDS (London), 2009, Vol.23 (16), p.2183-2190
8.
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
by Lee, Siow Ming, Prof
The lancet oncology, 2012, Vol.13 (11), p.1161-1170
9.
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
by Lee, Lennard Y W
The lancet oncology, 2022, Vol.23 (6), p.748-757
10.
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 M...
by Adams, Richard A, FRCP
The lancet oncology, 2011, Vol.12 (7), p.642-653
11.
No expectation to share incidental findings in genomic research
by Middleton, Anna
The Lancet (British edition), 2015, Vol.385 (9975), p.1289-1290
12.
Effects of chronic and intermittent cocaine treatment on dominance, aggression, and oxytocin levels in post-lactational rats
by Johns, Josephine M
Psychopharmacologia, 2010, Vol.211 (2), p.175-185
13.
A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease
by Nishioka, Kenya
Journal of neurology, neurosurgery and psychiatry, 2010, Vol.81 (4), p.391-395
14.
Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
by Moser, Gerhard
American journal of human genetics, 2015, Vol.96 (2), p.283-294
15.
Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease
by van der Walt, Joelle M
American journal of human genetics, 2003, Vol.72 (4), p.804-811
16.
Ultrasound facilitates minimally invasive parathyroidectomy in patients lacking definitive localization from preoperative sestamibi scan
by Davis, Matthew L., M.D
The American journal of surgery, 2007, Vol.194 (6), p.785-791
17.
Potential research participants support the return of raw data
by Middleton, Anna
Journal of medical genetics, 2015, Vol.52 (8), p.571
18.
Broadband futures: Content, connectivity and control
by Allen, Matthew
Media international Australia incorporating Culture & policy, 2014 (151), p.113-116
19.
Broadband Futures: Content, Connectivity and Control
by Allen, Matthew
Media international Australia incorporating Culture & policy, 2014, Vol.151 (1), p.113-116
20.
Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy
by VAN LEEUWEN, Marina T
AIDS (London), 2009, Vol.23 (16), p.2187-2194
